Year: 2022
Type: editorial
Abstract: More than 15 years ago, the results of the pivotal trials supporting the intravitreal use of ranibizumab were published [...].
Source: Journal of Personalized Medicine
DOI: 10.3390/jpm12040581
Authors: Andreas Ebneter, Peter D. Westenskow
Institution: F. Hoffmann-La Roche AG
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,094
OpenAlex ID: W4224314068